Literature DB >> 20697350

The proximal signaling network of the BCR-ABL1 oncogene shows a modular organization.

B Titz1, T Low, E Komisopoulou, S S Chen, L Rubbi, T G Graeber.   

Abstract

BCR-ABL1 is a fusion tyrosine kinase, which causes multiple types of leukemia. We used an integrated proteomic approach that includes label-free quantitative protein complex and phosphorylation profiling by mass spectrometry to systematically characterize the proximal signaling network of this oncogenic kinase. The proximal BCR-ABL1 signaling network shows a modular and layered organization with an inner core of three leukemia transformation-relevant adaptor protein complexes (Grb2/Gab2/Shc1 complex, CrkI complex and Dok1/Dok2 complex). We introduced an 'interaction directionality' analysis, which annotates static protein networks with information on the directionality of phosphorylation-dependent interactions. In this analysis, the observed network structure was consistent with a step-wise phosphorylation-dependent assembly of the Grb2/Gab2/Shc1 and the Dok1/Dok2 complexes on the BCR-ABL1 core. The CrkI complex demonstrated a different directionality, which supports a candidate assembly on the Nedd9 (Hef1, CasL) scaffold. As adaptor protein family members can compensate for each other in leukemic transformation, we compared members of the Dok and Crk protein families and found both overlapping and differential binding patterns. We identified an additional level of regulation for the CrkII protein via binding to 14-3-3 proteins, which was independent from its inhibitory phosphorylation. We also identified novel components of the inner core complexes, including the kinases Pragmin (Sgk223) and Lrrk1 (Lrrk2 paralog). Pragmin was found as a component of the CrkI complex and is a potential link between BCR-ABL1/CrkI and RhoA signaling. Lrrk1 is an unusual kinase with a GTPase domain. We detected Lrrk1 as a component of the Grb2/Gab2/Shc1 complex and found that it functionally interacts with the regulator of small GTPases Arap1 (Centd2) and possibly participates in the mitogen-activated protein kinase response to cellular stresses. This modular and phosphorylation-driven interaction network provides a framework for the integration of pleiotropic signaling effects of BCR-ABL1 toward leukemic transformation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20697350      PMCID: PMC5308218          DOI: 10.1038/onc.2010.331

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  90 in total

1.  ARAP1: a point of convergence for Arf and Rho signaling.

Authors:  Koichi Miura; Kerry M Jacques; Stacey Stauffer; Atsutaka Kubosaki; Kejin Zhu; Dianne Snow Hirsch; James Resau; Yi Zheng; Paul A Randazzo
Journal:  Mol Cell       Date:  2002-01       Impact factor: 17.970

2.  Differential regulation of adapter proteins Dok2 and Dok1 in platelets, leading to an association of Dok2 with integrin alphaIIbbeta3.

Authors:  S C Hughan; S P Watson
Journal:  J Thromb Haemost       Date:  2006-11-09       Impact factor: 5.824

3.  The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl.

Authors:  Yiping He; Jason A Wertheim; Lanwei Xu; Juli P Miller; Fredrick G Karnell; John K Choi; Ruibao Ren; Warren S Pear
Journal:  Blood       Date:  2002-04-15       Impact factor: 22.113

4.  Activation of aortic endothelial cells by oxidized phospholipids: a phosphoproteomic analysis.

Authors:  Alejandro Zimman; Sharon S Chen; Evangelia Komisopoulou; Bjoern Titz; Roxana Martínez-Pinna; Aarya Kafi; Judith A Berliner; Thomas G Graeber
Journal:  J Proteome Res       Date:  2010-06-04       Impact factor: 4.466

5.  Structure of the IRS-1 PTB domain bound to the juxtamembrane region of the insulin receptor.

Authors:  M J Eck; S Dhe-Paganon; T Trüb; R T Nolte; S E Shoelson
Journal:  Cell       Date:  1996-05-31       Impact factor: 41.582

6.  LRRK2 enhances oxidative stress-induced neurotoxicity via its kinase activity.

Authors:  Hye Young Heo; Ji-Min Park; Cy-Hyun Kim; Baek Soo Han; Kwang-Soo Kim; Wongi Seol
Journal:  Exp Cell Res       Date:  2009-09-19       Impact factor: 3.905

7.  BCR/ABL P190 transgenic mice develop leukemia in the absence of Crkl.

Authors:  Bianca Hemmeryckx; Anja Reichert; Meguru Watanabe; Vesa Kaartinen; Ron de Jong; Paul K Pattengale; John Groffen; Nora Heisterkamp
Journal:  Oncogene       Date:  2002-05-09       Impact factor: 9.867

8.  The intersectin 2 adaptor links Wiskott Aldrich Syndrome protein (WASp)-mediated actin polymerization to T cell antigen receptor endocytosis.

Authors:  M K McGavin; K Badour; L A Hardy; T J Kubiseski; J Zhang; K A Siminovitch
Journal:  J Exp Med       Date:  2001-12-17       Impact factor: 14.307

9.  A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in mice.

Authors:  Kara J Johnson; Ian J Griswold; Thomas O'Hare; Amie S Corbin; Marc Loriaux; Michael W Deininger; Brian J Druker
Journal:  PLoS One       Date:  2009-10-13       Impact factor: 3.240

10.  CDD: specific functional annotation with the Conserved Domain Database.

Authors:  Aron Marchler-Bauer; John B Anderson; Farideh Chitsaz; Myra K Derbyshire; Carol DeWeese-Scott; Jessica H Fong; Lewis Y Geer; Renata C Geer; Noreen R Gonzales; Marc Gwadz; Siqian He; David I Hurwitz; John D Jackson; Zhaoxi Ke; Christopher J Lanczycki; Cynthia A Liebert; Chunlei Liu; Fu Lu; Shennan Lu; Gabriele H Marchler; Mikhail Mullokandov; James S Song; Asba Tasneem; Narmada Thanki; Roxanne A Yamashita; Dachuan Zhang; Naigong Zhang; Stephen H Bryant
Journal:  Nucleic Acids Res       Date:  2008-11-04       Impact factor: 16.971

View more
  26 in total

1.  BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia.

Authors:  Oliver Hantschel; Wolfgang Warsch; Eva Eckelhart; Ines Kaupe; Florian Grebien; Kay-Uwe Wagner; Giulio Superti-Furga; Veronika Sexl
Journal:  Nat Chem Biol       Date:  2012-01-29       Impact factor: 15.040

2.  Oncogenic tyrosine kinases target Dok-1 for ubiquitin-mediated proteasomal degradation to promote cell transformation.

Authors:  Justyna A Janas; Linda Van Aelst
Journal:  Mol Cell Biol       Date:  2011-05-02       Impact factor: 4.272

3.  Differential signaling through p190 and p210 BCR-ABL fusion proteins revealed by interactome and phosphoproteome analysis.

Authors:  J A Cutler; R Tahir; S K Sreenivasamurthy; C Mitchell; S Renuse; R S Nirujogi; A H Patil; M Heydarian; X Wong; X Wu; T-C Huang; M-S Kim; K L Reddy; A Pandey
Journal:  Leukemia       Date:  2017-02-17       Impact factor: 11.528

Review 4.  Preclinical and clinical studies of the NEDD9 scaffold protein in cancer and other diseases.

Authors:  Elena Shagisultanova; Anna V Gaponova; Rashid Gabbasov; Emmanuelle Nicolas; Erica A Golemis
Journal:  Gene       Date:  2015-05-09       Impact factor: 3.688

5.  From Hen House to Bedside: Tracing Hanafusa's Legacy from Avian Leukemia Viruses to SRC to ABL and Beyond.

Authors:  Michael G Kharas; George Q Daley
Journal:  Genes Cancer       Date:  2010-12

6.  The crystal structure of pseudokinase PEAK1 (Sugen kinase 269) reveals an unusual catalytic cleft and a novel mode of kinase fold dimerization.

Authors:  Byung Hak Ha; Titus J Boggon
Journal:  J Biol Chem       Date:  2017-12-06       Impact factor: 5.157

7.  Structure, regulation, signaling, and targeting of abl kinases in cancer.

Authors:  Oliver Hantschel
Journal:  Genes Cancer       Date:  2012-05

Review 8.  The function of orthologues of the human Parkinson's disease gene LRRK2 across species: implications for disease modelling in preclinical research.

Authors:  Rebekah G Langston; Iakov N Rudenko; Mark R Cookson
Journal:  Biochem J       Date:  2016-02-01       Impact factor: 3.857

9.  Metabolic labeling of leucine rich repeat kinases 1 and 2 with radioactive phosphate.

Authors:  Jean-Marc Taymans; Fangye Gao; Veerle Baekelandt
Journal:  J Vis Exp       Date:  2013-09-18       Impact factor: 1.355

Review 10.  Role of ABL family kinases in cancer: from leukaemia to solid tumours.

Authors:  Emileigh K Greuber; Pameeka Smith-Pearson; Jun Wang; Ann Marie Pendergast
Journal:  Nat Rev Cancer       Date:  2013-07-11       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.